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Abstract
Importance
Subtle but important differences have been described in the way that male and female phy-
sicians care for their patients, with some evidence suggesting women are more likely to
adhere to best practice recommendations.
Objective
To determine if male and female physicians differ in their prescribing practices as measured
by the initiation of lower-than-recommended dose cholinesterase inhibitor (ChEI) drug ther-
apy for dementia management.
Design, setting, and participants
All community-dwelling Ontario residents aged 66 years and older with dementia and newly
dispensed an oral ChEI drug (donepezil, galantamine, or rivastigmine) between April 1,
2010 and June 30, 2016 were included.
Main outcome and measures
The association between physician sex and the initiation of a lower than recommended-
dose ChEI was examined using generalized linear mixed regression models, adjusting for
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Data Availability Statement: The dataset from this
study is held securely in coded form at the Institute
for Clinical Evaluative Sciences (ICES). While data
sharing agreements prohibit ICES from making the
dataset publicly available, access may be granted
to those who meet pre-specified criteria for
confidential access, available at www.ices.on.ca/
DAS. The full dataset creation plan and underlying
analytic code are available from the authors upon
request, understanding that the computer
programs may rely upon coding templates or
patient and physician characteristics. Data were stratified by specialty. Secondary analyses
explored the association between physician sex and cardiac screening as well as shorter
duration of the initial prescription.
Results
The analysis included 3,443 female and 5,811 male physicians and the majority (83%) were
family physicians, Female physicians were more likely to initiate ChEI therapy at a lower-
than-recommended dose (Adjusted odds ratio = 1.43,95% confidence interval = 1.17 to
1.74). Compared to their male counterparts, female physicians were also more likely to fol-
low other conservative prescribing practices including cardiac screening (55.1% vs. 49.2%,
P-value<0.001) around the time of ChEI initiation, and dispensing a shorter duration of initial
prescription (41.8% vs 35.5% P-value<0.001).
Conclusions
There is a statistically significant and important difference in ChEI prescribing patterns
between female and male physicians, suggesting that female physicians may be more care-
ful and conservative in their approaches. This will inform future research to determine if
patients receiving lower-than-recommended initial doses also have better outcomes.
Introduction
A growing body of evidence supports differences in the style of medicine practiced by physi-
cians according to their sex and gender. Relative to male physicians, evidence suggests that
female physicians spend more time with their patients[1], provide more counselling about
unhealthy behaviours[2], are more likely to adhere to guidelines[3] and deliver recommended
screening[4, 5], and offer more follow-up care[1]. Taken collectively, these differences suggest
that female physicians pursue a more careful and conservative approach to patient manage-
ment. There is also some evidence that this approach may result in female physicians provid-
ing better outcomes including: enhanced management of patients with certain chronic
conditions[6], fewer emergency room visits or hospitalizations[7], lower hospital readmission
and mortality rates[8], and better postoperative outcomes[9].
In the context of drug prescribing, the most frequent physician intervention, differences
in the process of drug prescribing between male and female physicians has not been well
described. Initiating a drug therapy at a low-dose is one measure of a more careful and conser-
vative prescribing practice because adverse events are often dose-related [10]. Careful is
defined as “applying care, solicitous attention, or pains to what one has to do; heedful, pains-
taking, attentive to one’s work”[11]. Conservative is defined as “conserves, or favours the con-
servation of, an existing structure or system; designating a person, movement, outlook, etc.,
averse to change or innovation and holding traditional ideas and values” [12]. Prescribing low-
dose therapy is a well-documented practice used to minimize dose-related adverse events
while providing benefits [10]. For some frequently used drug therapies, this dose is lower than
the lowest manufactured dose and requires pill-splitting [10]. Conventional wisdom in geriat-
ric medicine is “start low and go slow”. Where possible drug therapy should be initiated in an
older individual at a low-dose[13].
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Cholinesterase inhibitor (ChEI) drug therapy provides an excellent model to explore subtle
differences in the way that female and male physicians prescribe low-dose drug therapy. First,
ChEI therapy is widely used internationally because it is one of the only drugs available for the
management of dementia. Second, ChEI therapy provides only modest benefit on cognition,
and some evidence challenges the scientific basis for recommending this therapy[14]. Finally,
this therapy is associated with dose-related adverse events [15]. As such there is little urgency
to achieve a maximum therapeutic dose quickly, making it important to consider a more care-
ful and conservative approach to drug initiation to promote patient safety [16]. This model
provides the opportunity to learn about the small number of physicians who prescribe a lower-
than recommended staring dose of a ChEI therapy suggesting that they are following a more
careful and conservative approach to their prescribing.
To explore more careful and conservative prescribing practices between female and male
physicians, we examined incident use of ChEI drug therapy in a population-based cohort of
older adults with dementia. Analyses were conducted separately by physician speciality.
Materials and methods
Data sources
We conducted a population-based retrospective cohort study using administrative healthcare
data from Ontario, Canada. Ontario has a population of close to 1.8 million adults aged 65 and
older who have universal health and drug coverage. These data have been used for a range of
studies exploring drug therapy in older adults.[17–19] All older adults receive universal health
coverage that includes most physician services, hospital admissions, and outpatient prescrip-
tion drugs available through the Ontario Drug Benefit (ODB) Plan. This study used nine
administrative healthcare databases that were linked using unique encoded identifiers and
analyzed at the Institute for Clinical Evaluative Sciences (ICES). All data in the study were fully
anonymized. The information about the patient and physician records is shown in S1 File.
This study was approved by the Research Ethics Board of Sunnybrook Health Sciences
Centre.
Cohort definition
All community-dwelling Ontario residents aged 66 years and older with dementia and newly
dispensed an oral ChEI drug (donepezil, galantamine, or rivastigmine) between April 1, 2010
and June 30, 2016 were included. The N-methyl-D-aspartate receptor antagonist memantine
was not included because it is not reimbursed through the ODB. A lower age limit of 66 years
was used to allow for at least one year of enrolment in the ODB program. The index date was
the first dispensed ChEI in the time window. New users were defined as those who had not
received another ChEI prescription in the year prior to index. To be considered community-
dwelling, individuals could not reside in a nursing home in the year prior to initiating ChEI
therapy. Nursing home residents were excluded because they differ from older adults in the
community in several ways including their frailty, comorbidity, as well as the lower likelihood
of newly initiating a ChEI. A validated data algorithm[20] based on hospital diagnoses, physi-
cian records, and prescription drug claims was used to identify individuals with prevalent
dementia[20].
Exposure: Sex of the prescribing physician
Each patient newly dispensed a ChEI was assigned to a prescribing physician. The prescribing
physician was identified using unique encoded physician identifiers in the ODB database.
Comparison of prescribing practices for older adults treated by female versus male physicians
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These physician identifiers permit linkage with the ICES Physician Database. We excluded
patients whose physician identifier was missing or whose profile did not include their sex.
Primary outcomes: More careful and conservative prescribing practice
The primary outcome measure was the initiation of low-dose ChEI therapy and defined as a
lower-than-recommended starting dose. For ChEI therapy, some resources recommend taking
a more careful and conservative approach and starting at lower-than-recommended starting
doses[21, 22]. This is because like many drug therapies, ChEI adverse events are dose-related
[15]. For example, the donepezil product monograph[23] recommends not increasing the
dose for frail older women beyond the recommended starting dose (i.e. 5 mg)[24] to prevent
dose-related adverse events.
The initial dose of the ChEI therapy was calculated using information available from ODB
including the quantity of the drug dispensed (e.g. number of tablets), the number of days sup-
plied, and the drug identification number (DIN). The DIN signifies information about each
drug including strength. For example, if a patient was dispensed a 30-day supply of a 5 mg tab-
let of donepezil and given 30 tablets, their dose was classified as 5 mg per day.
Each ChEI therapy was assigned to one of three mutually exclusive dose categories: lower-
than-recommended starting dose, recommended starting dose, higher-than-recommended
starting dose based on dosing recommendations provided in standard drug prescribing text-
books[24], the product monographs[15, 23, 25] and using an approach followed in our prior
research[26] (S1 Table).
Secondary outcomes: Cardiac screening and shorter duration of
prescription
Screening for possible cardiac contraindications to ChEI use prior to the index date was con-
sidered as secondary outcome and considered as an additional aspect of a more careful and
conservative practice. This is because ChEI therapy can cause bradycardia or syncopal epi-
sodes[27]. Product monographs for donepezil[23], galantamine[15] and rivastigmine[25] rec-
ommend that ChEI should not be used in those with cardiac conduction abnormalities[24].
Our hypothesis was that a more careful and conservative prescriber would screen for these car-
diac contraindications prior to initiating ChEI. This measure was operationalized as evidence
of cardiac screening (i.e. an assessment by a cardiologist, an electrocardiogram (ECG), or a
Holter monitor) obtained in the six months prior to initiating a ChEI therapy. The six-month
time period was selected because we believed it represented a time period where the assess-
ments would be considered current.
Dispensing initial prescription for a short duration, which may facilitate monitoring of
adverse events, was also considered as a measure of a more careful and conservative practice.
The ChEI drug monograph recommends monitoring closely following drug initiation to avoid
or decrease adverse events[23]. Our hypothesis was that a more careful and conservative pre-
scriber would give a short duration of initial ChEI. Specifically, we measured the length in
days that the initial ChEI prescription was dispensed and less than 30 days was defined as a
short duration.
Covariates
Physician characteristics. Physician characteristics included age, years in practice, Cana-
dian versus international medical graduate status, specialty (i.e. family medicine/general prac-
tice, dementia specialist (i.e. geriatric medicine, neurology, psychiatry) or non-dementia
related specialist, and location of practice (i.e. urban or rural[28]).
Comparison of prescribing practices for older adults treated by female versus male physicians
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Patient characteristics. Patient demographic characteristics included their sex, age at
index date, low-income status (according to eligibility for a low-income subsidy in the ODB),
and urban versus rural residence. Time since the first documentation of dementia was mea-
sured as days between when an individual first met the criteria for the dementia algorithm and
the index prescription date. Comorbidity at the time of the index prescription was measured
using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) system (version 10.0.1) over a
two-year look-back period[29].
Statistical analyses
Within each group, the distribution of all baseline covariates between male and female physi-
cians was examined and a 0.10 cut-off in standardized differences, or a 10% difference, was
used to identify an imbalance between groups[30, 31].
To examine the association between physician sex and the initial dose of the incident ChEI,
we used a generalized linear mixed regression model. The model was adjusted for patient char-
acteristics. To account for potential correlation between patient outcomes within the same
physician, the models incorporated physician-specific random effects. We were selective in the
inclusion of physician characteristics in our models to avoid correcting for factors that may
reflect the gender differences that we are trying to study. As such, our analyses were stratified
based on medical specialty because the characteristics of the physician and their patients dif-
fered by specialty.
We took two steps to evaluate whether differences in dose dispensed between female and
male physicians could be accounted for by other physician characteristics. First, we stratified
our analyses by specialty (family medicine, dementia specialists, or non-dementia specialists)
because our preliminary analyses showed differences between speciality groups in their demo-
graphic characteristics and prescribing practices. Second, we adjusted for physicians’ number
of years practicing medicine.
Chi-square tests were used to assess the association between prescriber sex and each of the
secondary outcomes (cardiac screening and shorter duration of initial prescription).
Analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary,
North Carolina).
Results
Demographic characteristics
The cohort included 73,111 community-dwelling older adults with dementia who were 66
years of age and or older and were newly dispensed a ChEI; 43,572 (59.6%) were women and
29,539 (40.4%) were men (Table 1).
Physician characteristics
A total of 9,254 physician prescribers of ChEI therapy were identified (3,443 (37.2%) female and
5,811 (62.8%) male physicians). At the time of the first ChEI prescription for the patients in the
cohort, male physicians had been in practice longer (median 30 years) than their female coun-
terparts (median 22 years, standard difference [SDif] = 0.66). Compared to male physicians,
females were younger (median age: 49 vs. 58, SDif = 0.67), more likely to be in family medicine
(86.5% vs 81.6%, SDif = 0.15), had fewer patients initiated on ChEI (median number: 3 vs. 4,
SDif = 0.25) and were more likely to care for female patients (65.6% vs 56.8%, SDif = 0.18).
Use of a lower-than-recommended initial dose of ChEI therapy differed by physician spe-
cialty. Among those in family medicine, 4.1% dispensed the initial ChEI therapy at a lower-
Comparison of prescribing practices for older adults treated by female versus male physicians
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Table 1. Physician and patient characteristics of older adults with dementia and initiated cholinesterase inhibitor, by physician speciality.
Characteristic Overall Family Medicine Dementia Specialist
(Geriatric Medicine,
Psychiatry, or Neurology)
Non-Dementia Specialist
Female
Physician
(n = 3,443)
Male
Physician
(n = 5,811)
SDif Female
Physician
(n = 2,979)
Male
Physician
(n = 4,739)
SDif Female
Physician
(n = 253)
Male
Physician
(n = 486)
SDif Female
Physician
(n = 211)
Male
Physician
(n = 586)
SDif
Physicians
Age in years
Median(IQR) 49 (41–58) 58 (48–66) 0.67 49 (40–58) 58 (49–67) 0.69 50 (42–58) 58 (47–66) 0.55 47 (40–58) 56 (45–66) 0.57
Years in practice
Median(IQR) 22 (13–30) 30 (22–40) 0.66 22 (13–30) 30 (22–40) 0.67 22 (14–30) 30 (21–40) 0.63 21 (13–30) 29 (18–40) 0.6
Canadian medical
graduate
2,504
(72.7%)
4,139
(71.2%)
0.03 2,198
(73.8%)
3,491
(73.7%)
0 172
(68.0%)
265 (54.5%) 0.28 134
(63.5%)
383
(65.4%)
0.04
Location of practice:
Missing 44 (1.3%) 54 (0.9%) 0.03 38 (1.3%) 46 (1.0%) 0.03 < = 5
(1.6%)
< = 5
(0.6%)
0.09 < = 5
(0.9%)
< = 5
(0.9%)
0.01
Urban 3,068
(89.1%)
5,116
(88.0%)
0.03 2,616
(87.8%)
4,072
(85.9%)
0.06 247
(97.6%)
477 (98.1%) 0.04 205
(97.2%)
567
(96.8%)
0.02
Rural 331 (9.6%) 641 (11.0%) 0.05 325 (10.9%) 621 (13.1%) 0.07 < = 5
(0.8%)
6 (1.2%) 0.04 < = 5
(1.9%)
14 (2.4%) 0.03
Number of patients
initiated cholinesterase
inhibitor
Median(IQR) 3 (1–6) 4 (1–9) 0.25 3 (1–6) 4 (2–9) 0.4 7 (1–31) 4 (1–19) 0.2 1 (1–3) 1 (1–2) 0.22
Dementia Patients
Number of patients N = 23,139 N = 49,972 N = 13,655 N = 33,945 N = 8,522 N = 14,315 N = 962 N = 1,712
Sex
Female 15,176
(65.6%)
28,396
(56.8%)
0.18 9,443
(69.2%)
19,439
(57.3%)
0.25 5,171
(60.7%)
8,003
(55.9%)
0.1 562
(58.4%)
954
(55.7%)
0.05
Age, years
66–69 1,204 (5.2%) 2,586
(5.2%)
0 605 (4.4%) 1,429
(4.2%)
0.01 565 (6.6%) 1,073
(7.5%)
0.03 34 (3.5%) 84 (4.9%) 0.07
70–74 2,920
(12.6%)
6,113
(12.2%)
0.01 1,561
(11.4%)
3,751
(11.1%)
0.01 1,219
(14.3%)
2,167
(15.1%)
0.02 140
(14.6%)
195
(11.4%)
0.09
75–79 5,156
(22.3%)
10,965
(21.9%)
0.01 2,891
(21.2%)
7,121
(21.0%)
0 2,017
(23.7%)
3,470
(24.2%)
0.01 248
(25.8%)
374
(21.8%)
0.09
80–84 6,654
(28.8%)
14,239
(28.5%)
0.01 3,944
(28.9%)
9,798
(28.9%)
0 2,453
(28.8%)
3,947
(27.6%)
0.03 257
(26.7%)
494
(28.9%)
0.05
85–89 5,207
(22.5%)
11,302
(22.6%)
0 3,256
(23.8%)
8,125
(23.9%)
0 1,741
(20.4%)
2,777
(19.4%)
0.03 210
(21.8%)
400
(23.4%)
0.04
90+ 1,998 (8.6%) 4,767
(9.5%)
0.03 1,398
(10.2%)
3,721
(11.0%)
0.02 527 (6.2%) 881 (6.2%) 0 73 (7.6%) 165 (9.6%) 0.07
Low-income senior 5,005
(21.6%)
10,892
(21.8%)
0 2,980
(21.8%)
7,463
(22.0%)
0 1,761
(20.7%)
3,010
(21.0%)
0.01 264
(27.4%)
419
(24.5%)
0.07
Rural residence 2,734
(11.8%)
6,502
(13.0%)
0.04 2,209
(16.2%)
5,344
(15.7%)
0.01 460 (5.4%) 1,051
(7.3%)
0.08 65 (6.8%) 107 (6.3%) 0.02
Time since the first
documentation of
dementia prior to cohort
entry
0 days (same day as
cohort entry)
12,348
(53.4%)
29,914
(59.9%)
0.13 8,020
(58.7%)
22,173
(65.3%)
0.14 3,851
(45.2%)
6,776
(47.3%)
0.04 477
(49.6%)
965
(56.4%)
0.14
1–179 days 5,570
(24.1%)
9,894
(19.8%)
0.1 2,911
(21.3%)
5,605
(16.5%)
0.12 2,392
(28.1%)
3,882
(27.1%)
0.02 267
(27.8%)
407
(23.8%)
0.09
(Continued)
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than-recommended dose, compared to 6.1% of dementia specialists (Table 2). Further, the
rate of lower-than-recommended initial dose therapy use differed within dementia specialists,
with geriatricians having the highest rate of lower-than-recommended initial dose prescribing
(7.7% in geriatric medicine, 6.8% in psychiatry, and 1.5% in neurology).
Differences between prescribing patterns of male and female physicians
Primary outcome. Among all 9,254 physicians, female physicians were significantly more
likely than male physicians to initiate ChEI therapy at a lower-than-recommended initial dose
(6.1%% vs 4.1%) and the adjusted odds ratio (AOR) was 1.34 (95% confidence interval (CI) =
1.08–1.65) (Table 3). Among the 7,718 family medicine physicians, female physicians were sig-
nificantly more likely than male physicians to initiate ChEI therapy at a lower-than-recom-
mended initial dose (5.2% vs 3.7%) and the AOR was 1.31 (95% CI = 1.06–1.62) (Table 3). The
Table 1. (Continued)
Characteristic Overall Family Medicine Dementia Specialist
(Geriatric Medicine,
Psychiatry, or Neurology)
Non-Dementia Specialist
Female
Physician
(n = 3,443)
Male
Physician
(n = 5,811)
SDif Female
Physician
(n = 2,979)
Male
Physician
(n = 4,739)
SDif Female
Physician
(n = 253)
Male
Physician
(n = 486)
SDif Female
Physician
(n = 211)
Male
Physician
(n = 586)
SDif
180–364 days 1,481 (6.4%) 2,649
(5.3%)
0.05 697 (5.1%) 1,485
(4.4%)
0.03 725 (8.5%) 1,083
(7.6%)
0.03 59 (6.1%) 81 (4.7%) 0.06
1–2 years 1,368 (5.9%) 2,642
(5.3%)
0.03 683 (5.0%) 1,550
(4.6%)
0.02 624 (7.3%) 1,007
(7.0%)
0.01 61 (6.3%) 85 (5.0%) 0.06
2+ years 2,372
(10.3%)
4,873
(9.8%)
0.02 1,344 (9.8%) 3,132
(9.2%)
0.02 930
(10.9%)
1,567
(10.9%)
0 98 (10.2%) 174
(10.2%)
0
Aggregated diagnosis
groups (ADGs)
0–4 2,593
(11.2%)
6,304
(12.6%)
0.04 1,799
(13.2%)
4,859
(14.3%)
0.03 729 (8.6%) 1,290
(9.0%)
0.02 65 (6.8%) 155 (9.1%) 0.09
5–9 9,949
(43.0%)
22,373
(44.8%)
0.04 6,000
(43.9%)
15,409
(45.4%)
0.03 3,592
(42.1%)
6,304
(44.0%)
0.04 357
(37.1%)
660
(38.6%)
0.03
10+ 10,597
(45.8%)
21,295
(42.6%)
0.06 5,856
(42.9%)
13,677
(40.3%)
0.05 4,201
(49.3%)
6,721
(47.0%)
0.05 540
(56.1%)
897
(52.4%)
0.08
Concurrent medications
Median (IQR) 4 (2–7) 4 (2–7) 0 4 (2–7) 5 (2–7) 0.01 4 (2–7) 4 (2–7) 0.03 5 (3–8) 5 (3–7) 0.05
0 (ChEI only) 1,281 (5.5%) 2,990
(6.0%)
0.02 706 (5.2%) 1,921
(5.7%)
0.02 532 (6.2%) 987 (6.9%) 0.03 43 (4.5%) 82 (4.8%) 0.02
1–4 10,413
(45.0%)
22,279
(44.6%)
0.01 6,164
(45.1%)
14,962
(44.1%)
0.02 3,886
(45.6%)
6,665
(46.6%)
0.02 363
(37.7%)
652
(38.1%)
0.01
5–9 9,320
(40.3%)
20,157
(40.3%)
0 5,511
(40.4%)
13,842
(40.8%)
0.01 3,408
(40.0%)
5,545
(38.7%)
0.03 401
(41.7%)
770
(45.0%)
0.07
10+ 2,125 (9.2%) 4,546
(9.1%)
0 1,274 (9.3%) 3,220
(9.5%)
0.01 696 (8.2%) 1,118
(7.8%)
0.01 155
(16.1%)
208
(12.1%)
0.11
ChEI type
Donepezil 17,870
(77.2%)
38,572
(77.2%)
0 10,948
(80.2%)
26,822
(79.0%)
0.03 6,176
(72.5%)
10,467
(73.1%)
0.01 746
(77.5%)
1,283
(74.9%)
0.06
Galantamine 4,244
(18.3%)
9,653
(19.3%)
0.02 2,285
(16.7%)
6,042
(17.8%)
0.03 1,782
(20.9%)
3,251
(22.7%)
0.04 177
(18.4%)
360
(21.0%)
0.07
Rivastigmine 1,025 (4.4%) 1,747
(3.5%)
0.05 422 (3.1%) 1,081
(3.2%)
0.01 564 (6.6%) 597 (4.2%) 0.11 39 (4.1%) 69 (4.0%) 0
SDif = Standardized difference, IQR = Interquartile range, ChEI = Cholinesterase inhibitor
https://doi.org/10.1371/journal.pone.0205524.t001
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trend was similar for dementia specialists (AOR = 3.68, 95% CI = 2.47–5.49), but not for non-
dementia specialists (AOR = 1.27, 95% CI = 0.69–2.34).
Among the 739 dementia specialists, sex-specific differences were similar but higher than
those found in family medicine alone (geriatricians (AOR = 2.76, 95% CI = 1.39–5.51), psychi-
atrists (AOR = 3.00, 95% CI = 1.48–6.08), and neurologists (AOR = 3.25, 95% CI = 1.73–6.11).
Secondary outcomes. Both female family physicians and specialists were more likely to
have patients who had a cardiac screening prior to initiating a ChEI (55.1% vs. 49.2%, P-
value<0.001). (Table 2).
Overall, female physicians were more likely to prescribe a shorter duration (30 days or less)
of initial ChEI prescription (41.8% vs. 35.5%, P-value<0.001). Among the family medicine
physicians, dementia and non-dementia specialists, female physicians were more likely to pre-
scribe a shorter duration (30 days or less) of initial ChEI prescription (37.3% vs. 34.3%, P-
value<0.001 for family medicine, 48.7% vs. 38.5%, P-value<0.001 for dementia specialist, and
44.4% vs. 34.5%, P-value<0.001 for non-dementia specialists).
Discussion
Our study is among the first to demonstrate statistically significant and consistent differences
in prescribing patterns between female and male physicians. This suggests that female pre-
scribers have a tendency towards more careful and conservative prescribing practices when
Table 2. Prescribing carefulness measurement by physician specialty.
Characteristic Overall Family Medicine Dementia Specialist
(Geriatric Medicine, Psychiatry,
or Neurology)
Non-Dementia Specialist
Female
Physician
(n = 3,443)
Male
Physician
(n = 5,811)
P Female
Physician
(n = 2,979)
Male
Physician
(n = 4,739)
P Female
Physician
(n = 253)
Male
Physician
(n = 486)
P Female
Physician
(n = 211)
Male
Physician
(n = 586)
P
Primary outcome
Initial ChEI starting
dose
Lower-than-
recommended
1,418
(6.1%)
2,034
(4.1%)
< .001 706 (5.2%) 1,264
(3.7%)
< .001 684 (8.0%) 712 (5.0%) < .001 28 (2.9%) 58 (3.4%) < .001
Recommended 20,139
(87.0%)
44,130
(88.3%)
11,727
(85.9%)
29,602
(87.2%)
7,531
(88.4%)
12,992
(90.8%)
881
(91.6%)
1,536
(89.7%)
Higher-than-
recommended
1,582
(6.8%)
3,808
(7.6%)
1,222
(8.9%)
3,079
(9.1%)
307 (3.6%) 611 (4.3%) 53 (5.5%) 118 (6.9%)
Secondary outcomes
Cardiac screening
(ECG/Holter or
Cardiologist assessment
(% in last 6 months)
12,760
(55.1%)
24,571
(49.2%)
< .001 7,043
(51.6%)
15,566
(45.9%)
< .001 5,028
(59.0%)
7,884
(55.1%)
< .001 689
(71.6%)
1,121
(65.5%)
0.001
ECG or Holter 12,118
(52.4%)
23,341
(46.7%)
< .001 6,669
(48.8%)
14,774
(43.5%)
< .001 4,782
(56.1%)
7,489
(52.3%)
< .001 667
(69.3%)
1,078
(63.0%)
< .001
Cardiologist
assessment
6,691
(28.9%)
11,881
(23.8%)
< .001 3,473
(25.4%)
7,089
(20.9%)
< .001 2,825
(33.1%)
4,189
(29.3%)
< .001 393
(40.9%)
603
(35.2%)
0.004
Duration of initial
prescription
Less than 30 days 9,673
(41.8%)
17,734
(35.5%)
< .001 5,094
(37.3%)
11,629
(34.3%)
< .001 4,152
(48.7%)
5,515
(38.5%)
< .001 427
(44.4%)
590
(34.5%)
< .001
P = P-value, ChEI = cholinesterase inhibitor.
ECG = electrocardiogram.
https://doi.org/10.1371/journal.pone.0205524.t002
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prescribing a widely used dementia drug therapy. This finding was consistent whether they
were family medicine physicians, dementia specialist or other types of specialists. More specifi-
cally, our data indicate that female physicians were more likely than male physicians to follow
the geriatric medicine maxim “start low and go slow” and prescribe a lower-than-recom-
mended starting dose. We also demonstrated a similar pattern with other closely related mea-
sures. Specifically, patients prescribed ChEI by female physicians were more likely to have had
cardiac screening (prior assessment by a cardiologist or ECG or Holter monitor) and to be dis-
pensed a shorter duration of medication thereby facilitating monitoring for adverse events.
We are unaware of prior research that has studied sex and gender differences between male
and female physicians in the prescribing process. Our findings concur with interdisciplinary
research on sex and gender differences in risk perception and behaviour[32]. A meta-analysis
examining 150 studies comparing risk-taking tendencies of men and women showed that
almost all types of risk-taking were more frequent in men[33]. A study of college students
asked men and women to report their perception and preferences related to risk-taking sce-
narios. Women were less likely to take risks and this was related to a perceived likelihood of a
negative outcome[34]. This may be relevant to adverse drug events as they are perceived as a
negative outcome. There is a suggestion from the financial sector research that women take
Table 3. Association between physician sex and initial cholinesterase inhibitor dose prescribed.
Groups Physician
Sex
Unadjusted Patient adjusted�
Lower-than-
Recommended initial
dose��
Higher-than-
Recommended
initial dose��
Lower-than-
Recommended initial
dose��
Higher-than-
Recommended initial
dose��
OR (95%
CI)
P-value OR (95%
CI)
P-value AOR (95%
CI)
P-value AOR (95%
CI)
P-value
Overall Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 1.43
(1.17–1.74)
0.0004 0.90
(0.78–1.03)
0.1369 1.34
(1.08–1.65)
0.0068 0.89
(0.77–1.03)
0.1211
Family Medicine/General practice Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 1.33
(1.07–1.64)
0.0087 0.91
(0.79–1.04)
0.1775 1.31
(1.06–1.62)
0.0121 0.93
(0.80–1.07)
0.2847
Dementia Specialist (Geriatric Medicine, Psychiatry,
Neurology)
Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 3.81
(2.54–5.72)
< .0001 0.76
(0.53–1.08)
0.1198 3.68
(2.47–5.49)
< .0001 0.78
(0.55–1.10)
0.1572
Geriatric Medicine Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 2.84
(1.45–5.56)
0.0023 1.29
(0.83–2.00)
0.2587 2.76
(1.39–5.51)
0.0039 1.33
(0.85–2.09)
0.2087
Psychiatry Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 3.17
(1.58–6.37)
0.0012 0.58
(0.34–0.98)
0.0427 3.00
(1.48–6.08)
0.0023 0.60
(0.36–0.99)
0.0440
Neurology Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 3.27
(1.76–6.06)
0.0002 1.14
(0.57–2.28)
0.7168 3.25
(1.73–6.11)
0.0003 1.17
(0.58–2.35)
0.6593
Non Dementia Specialist Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Female 1.34
(0.74–2.45)
0.3355 1.05
(0.64–1.72)
0.8366 1.27
(0.69–2.34)
0.4358 1.02
(0.62–1.67)
0.9400
�Adjusted for patient age (continuous), sex, income quintile, rural residence, number of ADGs (continuous), acute myocardial infarction, asthma, angina, arrhythmia,
cancer, diabetes, congestive heart failure, hypertension, stroke, liver disease, renal disease, mood/anxiety disorders, and number of concurrent medications used.
�� Compared to recommended initial dose
ref: reference category.
https://doi.org/10.1371/journal.pone.0205524.t003
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fewer risks than men[35, 36]. A study from the investment industry found that women made
smaller investments in risky assets than men[37]. Risk aversion, whether financial or in medi-
cal practice, may be a more frequent behaviour of women. Initiating a drug therapy at a low-
dose, providing advanced cardiac screening for vulnerable patients, and providing the initial
prescription for a shorter period of time may also be consistent with evidence suggesting that
women are more cautious about preventing adverse drug events, and as such more careful and
conservative prescribers.
Our results add to the growing evidence that there are differences in the processes of care
received by patients managed by female physicians. This past year, Tsugawa et al[8] examined
the outcomes of older hospitalized patients treated by internists. They found that those treated
by female internists had lower mortality and readmission rate compared to similar patients
cared for by male internists. Further, Wallis et al[9] found that patients treated by female sur-
geons had a decrease in 30-day mortality. Our study suggests these differences also exist for
the process of drug prescribing. While we do not know if these differences in prescribing
processes will also lead to improved outcomes, these findings will inform future research
designed to determine if patients receiving lower-than-recommended initial doses also have
better outcomes. We do know that adverse events are often related to the drug ordering and
monitoring phase of the prescribing process[38]. It is important to understand these subtle
prescribing differences so that we can apply this information to improve prescribing practices
more generally.
Our choice of a lower-than-recommended initial dose as a measure of more careful and
conservative prescribing is supported by our findings that geriatricians and other dementia
specialists were more likely to initiate ChEI at low doses. Geriatricians are specialized in the
care of older adult. They have had specialist training and education about how best to prescribe
to vulnerable older adults. Thus, geriatricians’ prescribing practices for those with dementia
could be regarded as the model to follow when prescribing for this population. For instance,
geriatricians are taught to follow the start low and go slow philosophy when prescribing, partic-
ularly when the medication being prescribed is discretionary.
Prescribing a lower-than-recommended initial dose of a ChEI was not common in any spe-
cialty groups in our study. As expected, the vast majority (more than 80%) of prescribers were
in family medicine. While dementia specialists are the group most likely to prescribe low-dose
therapy, they account for only 1.3% of all prescribers. Given that relatively few older adults
receive care from a geriatricians, it is important that geriatricians develop strategies to share
their expertise in caring for the most vulnerable older adults more broadly[25].
Limitations
First, we acknowledge that we focused on the use of ChEI therapy and recognize that this is
only one type of drug therapy. Future research should explore this prescribing pattern for
other widely used drug therapies where a more careful and conservative approach may be jus-
tified. Irrespective, ChEI therapy is prescribed to millions of older people globally, and as such
subtle differences in prescribing processes could have a large impact at the population level.
Second, there are many measures that could be used to evaluate more careful and conservative
prescribing. We selected prescribing of lower-than-recommended doses of ChEI as our pri-
mary outcome measure. We recognize that the decision to initiate a therapy at this lower-
than-recommended dose in an older person needs to be considered in the clinical context. For
example, we recognize that starting low and being slow to titrate the dose could delay the mod-
est benefit observed at the higher therapeutic doses. On the other hand, when prescribing a
therapy of modest benefit such as a ChEI, it is important to do so in a way that minimizes the
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development of adverse events that may negatively impact quality of life and lead to the prema-
ture decision to discontinue the therapy before there is an opportunity for it to realize any
benefit. Third, we used evidence of having a cardiac screening prior to initiating a ChEI as a
measure of carefulness. While we do not know if the physician doing the prescribing ordered
these investigations, we do know that the investigations were obtained prior to the prescription
being dispensed. Finally, we identified providing an initial prescription of a shorter duration
as a way to estimate closer monitoring. We acknowledge that receipt of a longer prescription
does not preclude follow up. In some cases follow-up may happen in ways that are difficult to
detect with administrative data such as by community pharmacists or by nurses or there could
be physician follow up visits scheduled prior to the prescription renewal. Irrespective dispens-
ing a shorter initial duration of the prescription is one way to facilitate the monitoring process.
Our study provides important new information about prescribing behaviours. Lessons
learned from the more risk-averse, and more careful and conservative prescribing by female
physicians, may help to inform better prescribing for all. When prescribing a therapy of
modest benefit such as a ChEI, it is important to do so in a way that minimizes the develop-
ment of adverse events that may impair quality of life. Given the frequency of prescribing for
older adults, achieving this more careful and conservative approach to prescribing needs to be
considered.
Conclusions
Using a large cohort of older adults, our study found a consistent and statistically significant
difference in prescribing patterns between female and male physicians. This finding suggests
that female physicians may be more careful and conservative in their prescribing practices.
This will inform future research to determine if patients receiving lower-than-recommended
initial doses also have better outcomes.
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